Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Surgical oncology

Managing Your Care: Standard Treatment Strategies

At a Glance

For SFT, complete surgery with no tumor at the edge is the central treatment when the tumor can be removed. Radiation, selected embolization, pazopanib, other medicines, local treatments, and clinical trials may be considered based on location, stage, margins, subtype, and recurrence risk.

Treatment for Solitary Fibrous Tumor (SFT) is highly individualized. Because SFTs are rare and can behave unpredictably, your care should be managed by a multidisciplinary sarcoma team, which includes surgeons, oncologists, and radiologists who discuss your case to plan complex treatments and long-term care [1][2].

The Standard Strategy: Surgery

Complete surgical excision (removal) with negative margins (no tumor cells at the edge of the removed tissue) is the most important factor in preventing the tumor from returning locally [3][4].

  • Preoperative Embolization: Because SFTs often have a rich blood supply (hypervascularity), bleeding during the operation is a concern [5]. In selected cases, an interventional radiologist may consider a procedure called embolization before surgery. They use tiny particles to block the “feeding” blood vessels. However, this is not a routine, fixed step; timing varies, and it carries site-specific risks such as ischemic injury or unintended tissue damage depending on your anatomy [6][7].

The Role of Radiation Therapy

Radiation therapy is not an automatic requirement for every SFT patient. It is an individualized option typically used to improve “local control” (keeping the tumor from coming back in the same spot) [8].

  • Adjuvant Radiation: This is radiation given after surgery. Your multidisciplinary team may discuss it if the surgical margins were “close” or “positive,” or if the tumor had high-risk features [8].
  • Definitive Radiation: If a tumor cannot be safely removed because of its location, radiation may be used as an individualized local-control option to try to shrink or stabilize the tumor [9].

Systemic Therapies for Advanced Disease

If the tumor has spread (metastasized) or cannot be removed surgically, doctors use systemic therapies.

  1. Anti-Angiogenics (Pazopanib): Drugs like pazopanib work by interfering with the tumor’s ability to grow new blood vessels [10]. In advanced SFT, pazopanib has the strongest evidence for providing disease control. In clinical trials, around half of patients saw their tumors either shrink or stabilize (a “Choi response”), meaning the goal is often control rather than total cure [11][12].
  2. Temozolomide + Bevacizumab: This combination therapy has shown the ability to provide disease control in some patients, though the evidence is based on smaller, retrospective studies [13].
  3. Chemotherapy: Traditional chemotherapy (like anthracyclines) is generally less effective for most typical SFTs [14]. However, for the rare dedifferentiated subtype, chemotherapy may be considered on an individualized basis [15][F100].

Important Safety Note: Pazopanib

If you are prescribed an anti-angiogenic drug like pazopanib, you will need close monitoring. Common and sometimes severe side effects include:

  • Hypertension (High Blood Pressure): Baseline and frequent repeat monitoring is required.
  • Hepatotoxicity: Liver enzymes must be checked regularly through blood tests.
  • Wound Healing & Bleeding: These drugs can interfere with wound healing and increase bleeding risks around the time of any surgery.
    Never stop or change your treatment without discussing it with your oncology team.

A Menu of Treatment Options

Treatment sequencing is individualized. The following table provides examples of how the sarcoma team might approach different stages:

Stage of Disease Examples of Primary Options Examples of Supportive/Secondary Options
Localized Complete Surgical Excision [3] Preoperative Embolization if selected [7]
Close/Positive Margins Re-excision or Observation Adjuvant Radiation Therapy [8]
Unresectable Definitive Radiation or Systemic Therapy [9] Biopsy/Staging to guide local control
Metastatic Systemic Therapy (e.g., Pazopanib) [11] Local treatments (surgery/ablation) for specific lesions, or Clinical Trials

Individualized Monitoring

Regardless of the treatment you receive, SFT has a reported history of late recurrences. Your follow-up schedule must be individualized based on your risk, site, and treatment [4][16].

Common questions in this guide

What is the main treatment for a localized solitary fibrous tumor?
Complete surgical removal with no tumor cells at the edge, called negative margins, is the main treatment for a localized SFT and helps reduce the risk of local recurrence. Because SFT can be complex and highly vascular, a multidisciplinary sarcoma team may plan the operation and, in selected cases, preoperative embolization.
When might radiation therapy be recommended for SFT?
Radiation is not automatically needed for every SFT patient. A team may consider it after surgery when margins are close or positive or when the tumor has high-risk features, and it may be used to control a tumor that cannot be safely removed.
What treatments are used for advanced or metastatic SFT?
When SFT has spread or cannot be removed, doctors may use systemic treatment such as pazopanib or temozolomide with bevacizumab. Pazopanib has the strongest evidence for disease control in advanced SFT, while local treatments or clinical trials may be considered in selected situations.
What should I monitor if I take pazopanib for SFT?
Pazopanib can cause high blood pressure, liver injury, bleeding, and delayed wound healing. Your oncology team should check your blood pressure and liver blood tests regularly and coordinate the medicine around surgery; do not stop or change it without medical advice.
Is chemotherapy effective for solitary fibrous tumor?
Traditional chemotherapy is generally less effective for most typical SFTs. It may be considered individually for the rare dedifferentiated subtype, based on the tumor's features and the overall treatment plan.
How long will I need follow-up after SFT treatment?
Long-term follow-up is important because SFT can recur years after treatment. The schedule for scans and visits should be individualized according to the tumor's risk, location, and treatment.
Should my SFT case be reviewed by a sarcoma team?
Because SFT is rare and can behave unpredictably, care is best planned by a multidisciplinary sarcoma team when available. Surgeons, oncologists, radiologists, and other specialists can review the tumor's location, stage, margins, and treatment options together.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my tumor considered 'hypervascular,' and should we consult an interventional radiologist about preoperative embolization?
  2. 2.Given my margin status and mitotic count, what is the estimated benefit of adding radiation therapy to my treatment plan?
  3. 3.For my advanced disease, why would you choose pazopanib over the temozolomide and bevacizumab combination?
  4. 4.If my tumor is the 'dedifferentiated' subtype, should we consider anthracycline-based chemotherapy instead of anti-angiogenic drugs?
  5. 5.What are the specific side effects I should watch for with pazopanib, particularly regarding my blood pressure and liver function?
  6. 6.Does this hospital have a dedicated multidisciplinary sarcoma board that has reviewed my specific case?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Spinal Solitary Fibrous Tumors: An Original Multicenter Series and Systematic Review of Presentation, Management, and Prognosis.

    Apra C, El Arbi A, Montero AS, et al.

    Cancers 2022; (14(12)) doi:10.3390/cancers14122839.

    PMID: 35740510
  2. 2

    Solitary fibrous tumor.

    Davanzo B, Emerson RE, Lisy M, et al.

    Translational gastroenterology and hepatology 2018; (3()):94 doi:10.21037/tgh.2018.11.02.

    PMID: 30603730
  3. 3

    Clinical Characteristics and Outcomes for Solitary Fibrous Tumor (SFT): A Single Center Experience.

    DeVito N, Henderson E, Han G, et al.

    PloS one 2015; (10(10)):e0140362 doi:10.1371/journal.pone.0140362.

    PMID: 26469269
  4. 4

    Toward Better Understanding and Management of Solitary Fibrous Tumor.

    Kazazian K, Demicco EG, de Perrot M, et al.

    Surgical oncology clinics of North America 2022; (31(3)):459-483 doi:10.1016/j.soc.2022.03.009.

    PMID: 35715145
  5. 5

    Solitary fibrous tumor in the abdomen and pelvis: A case series with radiological findings and treatment recommendations.

    Fernandez A, Conrad M, Gill RM, et al.

    Clinical imaging 2018; (48()):48-54 doi:10.1016/j.clinimag.2017.10.002.

    PMID: 29028514
  6. 6

    Salvage preoperative embolization of an infratemporal solitary fibrous tumor: A case report with review of the literature.

    Yammine K, Nasser HA, Hadi U, et al.

    Medicine 2018; (97(13)):e0251 doi:10.1097/MD.0000000000010251.

    PMID: 29595682
  7. 7

    Resection of a giant thoracic solitary fibrous tumor treated with preoperative arterial coiling followed by a double-level thoracotomy.

    Cox J, Leesley H, DeAnda A, et al.

    Journal of surgical case reports 2023; (2023(1)):rjad008 doi:10.1093/jscr/rjad008.

    PMID: 36685116
  8. 8

    Extrameningeal solitary fibrous tumors-surgery alone or surgery plus perioperative radiotherapy: A retrospective study from the global solitary fibrous tumor initiative in collaboration with the Sarcoma Patients EuroNet.

    Haas RL, Walraven I, Lecointe-Artzner E, et al.

    Cancer 2020; (126(13)):3002-3012 doi:10.1002/cncr.32911.

    PMID: 32315454
  9. 9

    Diagnostics and Treatment of Extrameningeal Solitary Fibrous Tumors.

    Janik AM, Terlecka A, Spałek MJ, et al.

    Cancers 2023; (15(24)) doi:10.3390/cancers15245854.

    PMID: 38136399
  10. 10

    Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial.

    Martin-Broto J, Cruz J, Penel N, et al.

    The Lancet. Oncology 2020; (21(3)):456-466 doi:10.1016/S1470-2045(19)30826-5.

    PMID: 32066540
  11. 11

    Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.

    Martin-Broto J, Stacchiotti S, Lopez-Pousa A, et al.

    The Lancet. Oncology 2019; (20(1)):134-144 doi:10.1016/S1470-2045(18)30676-4.

    PMID: 30578023
  12. 12

    Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience.

    Maruzzo M, Martin-Liberal J, Messiou C, et al.

    Clinical sarcoma research 2015; (5()):5 doi:10.1186/s13569-015-0022-2.

    PMID: 25664166
  13. 13

    Solitary fibrous tumor/hemangiopericytoma treated with temozolomide plus bevacizumab: a report of four cases and literature review.

    Maeda O, Ohka F, Maesawa S, et al.

    Nagoya journal of medical science 2020; (82(4)):631-644 doi:10.18999/nagjms.82.4.631.

    PMID: 33311794
  14. 14

    Clinical Presentation, Natural History, and Therapeutic Approach in Patients with Solitary Fibrous Tumor: A Retrospective Analysis.

    Schöffski P, Timmermans I, Hompes D, et al.

    Sarcoma 2020; (2020()):1385978 doi:10.1155/2020/1385978.

    PMID: 32300277
  15. 15

    Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.

    Stacchiotti S, Saponara M, Frapolli R, et al.

    European journal of cancer (Oxford, England : 1990) 2017; (76()):84-92 doi:10.1016/j.ejca.2017.02.002.

    PMID: 28284173
  16. 16

    Solitary fibrous tumor/hemangiopericytoma: treatment results based on the 2016 WHO classification.

    Sung KS, Moon JH, Kim EH, et al.

    Journal of neurosurgery 2019; (130(2)):418-425 doi:10.3171/2017.9.JNS171057.

    PMID: 29521591

This page explains treatment strategies for SFT for informational purposes only and does not replace medical advice. Your multidisciplinary sarcoma team should tailor treatment and monitoring to your tumor and health.

Get notified when new evidence is published on Solitary Fibrous Tumor (SFT).

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.